12:54 PM EST - PharmaTher Inc : Is pleased to provide an update on the Company’s psilocybin pharmaceutical development programs. The Company is evaluating psilocybin as a potential treatment for methamphetamine use disorder with the University of Wisconsin-Madison through a clinical trial agreement. PharmaTher Inc
shares C.PHRM are trading unchanged at $0.34.
